Late Breaking Abstract - Effect of adjunctive tobramycin inhalation therapy in the treatment of ventilator-associated pneumonia: findings from the randomized VAPORISE trial
J. Stokker (Rotterdam, Netherlands), M. Karami (Amsterdam, Netherlands), R. Hoek (Rotterdam, Netherlands), D. Van Duijn (Rotterdam, Netherlands), P. Ormskerk (Rotterdam, Netherlands), F. Muskens (Rotterdam, Netherlands), J. Aerts (Rotterdam, Netherlands), D. Gommers (Rotterdam, Netherlands), M. van der Eerden (Rotterdam, Netherlands)
Source: International Congress 2019 – Recent developments in intensive care unit medicine
Session: Recent developments in intensive care unit medicine
Session type: Thematic Poster
Number: 4026
Disease area: Respiratory critical care, Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Stokker (Rotterdam, Netherlands), M. Karami (Amsterdam, Netherlands), R. Hoek (Rotterdam, Netherlands), D. Van Duijn (Rotterdam, Netherlands), P. Ormskerk (Rotterdam, Netherlands), F. Muskens (Rotterdam, Netherlands), J. Aerts (Rotterdam, Netherlands), D. Gommers (Rotterdam, Netherlands), M. van der Eerden (Rotterdam, Netherlands). Late Breaking Abstract - Effect of adjunctive tobramycin inhalation therapy in the treatment of ventilator-associated pneumonia: findings from the randomized VAPORISE trial. 4026
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Late Breaking Abstract - Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia: a randomised clinical trial Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020
Late Breaking Abstract - Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children: a randomized controlled trial Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020
Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial Source: Eur Respir J, 58 (2) 2002535; 10.1183/13993003.02535-2020 Year: 2021
Randomized, controlled trial of efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants Source: Eur Respir J 2006; 28: Suppl. 50, 488s Year: 2006
Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial Source: International Congress 2015 – Acute critical care: news from the ICU Year: 2015
Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016
Late Breaking Abstract: High-dose vitamin D3 during intensive phase treatment of pulmonary tuberculosis: A double-blind randomised controlled trial Source: Annual Congress 2010 - Clinical tuberculosis Year: 2010
Late Breaking Abstract - Severe pneumonia patients may could not benefit from antibiotic combination therapy and non-invasive ventilation(NIV), despite the advanced mode Source: International Congress 2018 – Non-invasive ventilation for acute respiratory failure Year: 2018
Procalcitonin-guided antibiotic therapy in acute exacerbations of COPD (AECOPD): a randomised trial - The ProCOLD Study Source: Eur Respir J 2005; 26: Suppl. 49, 464s Year: 2005
Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019
Late Breaking Abstract - Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid - Data from 38,820 outpatients. Source: International Congress 2019 – Comorbidities galore in respiratory patients Year: 2019
A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001
Evaluation of moxifloxacin (MXF) as empiric antibiotic therapy of CAP outpatients: A multicenter prospective study Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012
Late Breaking Abstract - Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia – The BESTCILIA randomized placebo-controlled trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Intensive care and infection Year: 2019
Changes in empirical initial antibiotic therapy in community-acquired pneumonia: assessment of clinical failure versus discordant therapy Source: Eur Respir J 2006; 28: Suppl. 50, 736s Year: 2006
Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study Source: Eur Respir J 2009; 34: 1364-1375 Year: 2009
Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006
Feasibility of shortening intravenous antibiotic therapy for bronchiectasis based on bacterial load: a proof-of-concept randomised controlled trial Source: Eur Respir J, 58 (6) 2004388; 10.1183/13993003.04388-2020 Year: 2021
Effect of de-escalation antibiotic therapy on hospital-acquired, ventilator associated, and healthcare-associated pneumonia: A systematic review and meta-analysis Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections Year: 2016
LATE-BREAKING ABSTRACT: Intravenous infusion of Chinese medicine xuebijing significantly improved clinical outcome in severe pneumonia patients in a multiple center randomized controlled clinical trials Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016